Trial Profile
A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary)
- Indications Gastrointestinal cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 18 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to completed.
- 25 Feb 2014 New trial record